New Recruiting Trial: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
WHY IT MATTERS
This is the first trial testing inebilizumab specifically in children with gMG—previous studies only included adults—so it could lead to the first approved treatment option for this age group.
Researchers are testing a new medicine called inebilizumab in children who have generalized myasthenia gravis (gMG), a rare condition where the immune system attacks muscles and causes weakness. This study will check how the medicine works in children's bodies, whether it's safe, and what side effects it might cause. The study is now accepting patients and is expected to start in April 2026.
NCT ID: NCT06987539 Title: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) Status: RECRUITING Phase: PHASE2 Sponsor: Amgen Start date: 2026-04-30 URL: https://clinicaltrials.gov/study/NCT06987539 Source: UniteRare clinical trials database
YOU CAN ACT ON THIS
If your child has generalized myasthenia gravis, contact the trial site listed on clinicaltrials.gov (NCT06987539) to ask if they qualify and learn about enrollment before recruitment closes.